Neurizon Therapeutics (NUZ) Stock Overview
A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NUZ Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Neurizon Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.095 |
| 52 Week High | AU$0.18 |
| 52 Week Low | AU$0.079 |
| Beta | 1.29 |
| 1 Month Change | 15.85% |
| 3 Month Change | -9.52% |
| 1 Year Change | -34.48% |
| 3 Year Change | 21.79% |
| 5 Year Change | -5.00% |
| Change since IPO | -98.94% |
Recent News & Updates
Recent updates
We Think Neurizon Therapeutics (ASX:NUZ) Needs To Drive Business Growth Carefully
Jun 12
Here's Why We're Watching Neurizon Therapeutics' (ASX:NUZ) Cash Burn Situation
Feb 21Here's Why We're Not Too Worried About PharmAust's (ASX:PAA) Cash Burn Situation
Apr 09Here's Why We're Not At All Concerned With PharmAust's (ASX:PAA) Cash Burn Situation
Mar 31Here's Why PharmAust Limited's (ASX:PAA) CEO Compensation Is The Least Of Shareholders Concerns
Nov 03Is PharmAust (ASX:PAA) In A Good Position To Deliver On Growth Plans?
May 30This Is The Reason Why We Think PharmAust Limited's (ASX:PAA) CEO Might Be Underpaid
Oct 14What Does PharmAust's (ASX:PAA) CEO Pay Reveal?
Feb 14Shareholder Returns
| NUZ | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 2.2% | 2.8% | 1.9% |
| 1Y | -34.5% | -21.5% | 8.3% |
Return vs Industry: NUZ underperformed the Australian Pharmaceuticals industry which returned -18.6% over the past year.
Return vs Market: NUZ underperformed the Australian Market which returned 7.9% over the past year.
Price Volatility
| NUZ volatility | |
|---|---|
| NUZ Average Weekly Movement | 11.8% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 9.5% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: NUZ has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: NUZ's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Michael Thurn | www.neurizon.com |
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases.
Neurizon Therapeutics Limited Fundamentals Summary
| NUZ fundamental statistics | |
|---|---|
| Market cap | AU$65.42m |
| Earnings (TTM) | -AU$16.59m |
| Revenue (TTM) | AU$1.54m |
Is NUZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NUZ income statement (TTM) | |
|---|---|
| Revenue | AU$1.54m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.54m |
| Other Expenses | AU$18.13m |
| Earnings | -AU$16.59m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,079.02% |
| Debt/Equity Ratio | 0% |
How did NUZ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/20 05:47 |
| End of Day Share Price | 2026/02/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neurizon Therapeutics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.